Dow Jones Newswires: GlaxoSmithKline to buy Sierra Oncology for $1.9 billion

This post was originally published on this site

Pharmaceutical giant GlaxoSmithKline PLC said Wednesday that it is buying biopharmaceutical company Sierra Oncology Inc. for $1.9 billion, and backed its guidance.

GlaxoSmithKline
GSK,
+0.11%

GSK,

will pay $55 per share in cash, a 39% premium to its closing price of $39.52 on Tuesday. The deal has the support of Sierra’s
SRRA,
+3.10%

board as well as shareholders owning 28% of its stock.

Glaxo reaffirmed its guidance. It expects 2021-2026 sales growth of more than 5% and for 10% adjusted operating profit.

The deal is expected to close in the third quarter of this year.

Write to Ian Walker at ian.walker@wsj.com